Physician profile
Peter D Miller
NPI 1215911490
$4,672.20
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $382 · 2021: $1,432 · 2022: $1,466 · 2023: $428 · 2024: $55.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.32 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $846.14 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $503.73 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $454.47 | 2019-2023 | Stelara |
| Pfizer INC. | $396.23 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $127.15 | 2021-2022 | |
| Gilead Sciences, INC. | $126.33 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $126.26 | 2019-2023 | Ocaliva |
| Genzyme Corporation | $122.51 | 2022 | |
| Amgen INC. | $102.16 | 2020-2022 | |
| Celgene Corporation | $96.51 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $94.03 | 2019-2022 | |
| Qol Medical, LLC | $94.00 | 2022-2023 | Sucraid |
| Redhill Biopharma INC. | $85.77 | 2021-2022 | |
| Ardelyx, INC. | $85.51 | 2022-2023 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $72.66 | 2019 | |
| Nestle Healthcare Nutrition INC. | $62.01 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $55.85 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $34.34 | 2019-2022 | |
| Enterra Medical, INC. | $29.99 | 2022 | |
| Digestive Care, INC. | $27.77 | 2021 | |
| Braintree Laboratories, INC. | $26.85 | 2019-2022 | |
| Daiichi Sankyo INC. | $21.72 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.09 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2022 | |
| Allergan, INC. | $14.57 | 2019 | |
| Medtronic, INC. | $13.68 | 2021 | |
| Boston Scientific Corporation | $13.05 | 2019 | |
| Evoke Pharma, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.